keyword
MENU ▼
Read by QxMD icon Read
search

CRVO

keyword
https://www.readbyqxmd.com/read/28214955/ranibizumab-versus-aflibercept-for-macular-edema-due-to-central-retinal-vein-occlusion-18-month-results-in-real-life-data
#1
Irini Chatziralli, George Theodossiadis, Marilita M Moschos, Panagiotis Mitropoulos, Panagiotis Theodossiadis
PURPOSE: The objective of this study was to compare the anatomical and functional outcomes of ranibizumab versus aflibercept for the treatment of macular edema due to central retinal vein occlusion (CRVO) in routine clinical practice. METHODS: Participants in this observational study included 62 treatment-naïve patients with CRVO who received intravitreal injections of either ranibizumab or aflibercept. The demographic data, best-corrected visual acuity (BCVA) and spectral-domain optical coherence tomography (SD-OCT) characteristics were evaluated at baseline and at months 1, 2, 3, 6, 12 and 18 post-treatment...
February 18, 2017: Graefe's Archive for Clinical and Experimental Ophthalmology
https://www.readbyqxmd.com/read/28207609/ischemic-central-retinal-vein-occlusion-in-the-anti-vascular-endothelial-growth-factor-era
#2
Emily K Tam, Pamela Golchet, Madeline Yung, Francis C DeCroos, Marc Spirn, Lydia Lehmann-Clarke, Aude Ambresin, Irena Tsui
PURPOSE: Anti-vascular endothelial growth factor therapy has improved the prognosis for patients with central retinal vein occlusion (CRVO). However, most studies published to date exclude ischemic CRVO. The purpose of this study was to describe the outcome in eyes with ischemic CRVO treated with anti-vascular endothelial growth factor therapy. METHODS: Thirty-seven patients with ischemic CRVO from 3 centers were followed for at least 6 months. Data on patient demographic, vision status, and anti-vascular endothelial growth factor treatments were collected...
February 15, 2017: Retina
https://www.readbyqxmd.com/read/28161829/effect-of-oral-niacin-on-central-retinal-vein-occlusion
#3
Michael W Gaynon, Yannis M Paulus, Ehsan Rahimy, Janet L Alexander, Sam E Mansour
PURPOSE: Niacin, a treatment for dyslipidemia, is known to induce vasodilation as a secondary effect. Previous instances of patients with chronic central retinal vein occlusion (CRVO) and cystoid macular edema (CME) have been observed to spontaneously improve when placed on systemic niacin for hypercholesterolemia. The purpose of this study was to evaluate the effects of niacin on CRVO and associated ocular complications. METHODS: A prospective, single-center, non-randomized, interventional case series of niacin for CRVO was conducted...
February 4, 2017: Graefe's Archive for Clinical and Experimental Ophthalmology
https://www.readbyqxmd.com/read/28127735/effects-of-panretinal-laser-photocoagulation-on-the-corneal-nerve-plexus-and-retinal-nerve-fiber-layer-in-retinal-vein-occlusion
#4
Gulfidan Bitirgen, Selman Belviranli, Rayaz A Malik, Hurkan Kerimoglu, Ahmet Ozkagnici
PURPOSE: To determine the effects of panretinal photocoagulation (PRP) on corneal sub-basal nerve plexus (SBNP) and peripapillary retinal nerve fiber layer (RNFL) thickness in patients with unilateral central retinal vein occlusion (CRVO) who had previously undergone PRP treatment. METHODS: Sixty-four eyes of 32 patients (19 male, 13 female) with unilateral ischemic type CRVO who had undergone PRP treatment at least 6 months previously were included in this cross-sectional study...
January 23, 2017: European Journal of Ophthalmology
https://www.readbyqxmd.com/read/28124146/aniseikonia-in-various-retinal-disorders
#5
Fumiki Okamoto, Yoshimi Sugiura, Yoshifumi Okamoto, Takahiro Hiraoka, Tetsuro Oshika
PURPOSE: The purpose was to quantify and compare the severity of aniseikonia in patients undergoing vitrectomy for various retinal disorders. METHODS: We studied 357 patients with retinal disorders including epiretinal membrane (ERM), macular hole (MH), cystoid macular edema with branch / central retinal vein occlusion (BRVO-CME / CRVO-CME), diabetic macular edema (DME), macula-off rhegmatogenous retinal detachment (M-off RD), and macula-on RD (M-on RD) as well as 31 normal controls...
January 25, 2017: Graefe's Archive for Clinical and Experimental Ophthalmology
https://www.readbyqxmd.com/read/28103831/demographics-of-patients-receiving-intravitreal-anti-vegf-treatment-in-real-world-practice-healthcare-research-data-versus-randomized-controlled-trials
#6
F Ziemssen, N Feltgen, F G Holz, R Guthoff, A Ringwald, T Bertelmann, A Wiedon, C Korb
BACKGROUND: While randomized controlled trials (RCTs) are based on strict inclusion/exclusion criteria, non-interventional studies (NISs) might provide additional information to guide management in patients more representative to the real-world setting. The aim of this study was to compare baseline characteristics of patients receiving intravitreal treatment in the NIS OCEAN with those from published RCTs. METHODS: The ongoing OCEAN study enrolled patients treated with ranibizumab for neovascular age-related macular degeneration (nAMD), diabetic macular oedema (DME) or branch/central retinal vein occlusion (B/CRVO)...
January 19, 2017: BMC Ophthalmology
https://www.readbyqxmd.com/read/28098203/optical-coherence-tomography-angiography-microvascular-findings-in-macular-edema-due-to-central-and-branch-retinal-vein-occlusions
#7
Mastropasqua Rodolfo, Toto Lisa, Di Antonio Luca, Borrelli Enrico, Senatore Alfonso, Di Nicola Marta, Di Martino Giuseppe, Ciancaglini Marco, Paolo Carpineto
The aim of this study was to evaluate retinal and choriocapillaris vessel density using optical coherence tomography angiography (OCTA) in eyes with central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO) complicated by macular edema (ME). Sixty eyes of 60 patients with CRVO or BRVO and ME and 40 healthy subjects underwent measurements of superficial and deep foveal and parafoveal vessel density (FVD, PFVD) and choricapillary density using OCTA at baseline and 60 days after intravitreal dexamethasone implant (IVDEX)...
January 18, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28053503/assessment-of-ischemia-in-acute-central-retinal-vein-occlusion-from-inner-retinal-reflectivity-on-spectral-domain-optical-coherence-tomography
#8
David J Browning, Omar S Punjabi, Chong Lee
PURPOSE: To determine the relationship between different spectral domain optical coherence tomography (SD-OCT) signs of retinal ischemia in acute central retinal vein occlusion (CRVO) and whether they predict anterior segment neovascularization (ASNV). DESIGN: Retrospective, observational study. SUBJECTS: Thirty-nine consecutive patients with acute CRVO and 12 months of follow-up. METHODS: We graded baseline SD-OCTs for increased reflectivity of the inner retina, loss of definition of inner retinal layers, presence of a prominent middle-limiting membrane (p-MLM) sign, and presence of paracentral acute middle maculopathy (PAMM)...
2017: Clinical Ophthalmology
https://www.readbyqxmd.com/read/28031700/long-term-results-of-combination-therapy-using-anti-vegf-agents-and-dexamethasone-intravitreal-implant-for-retinal-vein-occlusion-an-investigational-case-series
#9
Michael A Singer, Michael E Jansen, Lyndon Tyler, Paul Woods, Faisal Ansari, Udit Jain, Joshua Singer, Darren Bell, Chelsey Krambeer
BACKGROUND: One limitation of anti-VEGF therapy is the need for monthly retreatment to maintain efficacy. The purpose of this study was to determine the duration of effect in eyes with macular edema (ME) secondary to branch or central retinal vein occlusion (BRVO or CRVO) treated with anti-VEGF therapy plus sustained-release dexamethasone (DEX implant; Ozurdex). MATERIALS AND METHODS: This open-label, interventional case series included 62 eyes with ME due to RVO, central foveal thickness (CFT) >300 μm, and best-corrected visual acuity (BCVA) of 20/40 or worse...
2017: Clinical Ophthalmology
https://www.readbyqxmd.com/read/28030428/outer-retinal-layer-changes-after-dexamethasone-implant-for-central-retinal-vein-occlusion
#10
Maurizio Battaglia Parodi, Pierluigi Iacono, Matteo Scaramuzzi, Francesco Bandello
PURPOSE: To analyze the outer retinal layer changes on spectral-domain optical coherence tomography after dexamethasone implant for the treatment of macular edema secondary to central retinal vein occlusions (CRVO). METHODS: Thirty patients affected by macular edema related to CRVO (8 patients less than 50 years of age with nonischemic CRVO [<50-niCRVO], 12 patients more than 50 years with niCRVO [>50-niCRVO], and 10 patients with ischemic CRVO [iCRVO]) were included in a prospective study...
December 23, 2016: Retina
https://www.readbyqxmd.com/read/28003785/central-retinal-vein-occlusion-associated-with-high-blood-levels-of-lipoprotein-a-is-lipoprotein-a-a-reliable-marker-for-identification-of-predisposed-individuals
#11
Piergiacomo Grassi, Alberto Salicone, Lorenzo Motta, Mario Salvatore Motta
To report a case of central retinal vein occlusion (CRVO) associated with abnormal elevation of Lipoprotein (a) [Lp(a)] plasma levels, without local or systemic risk factors. A 74-year-old man was referred to our department for cataract surgery in his left eye, and his anamnesis was negative for systemic diseases. Two months later, the patient presented with sudden visual loss in his operated eye, and comprehensive ophthalmic examination was performed, including Fluorescein Angiography (FA) and Optical Coherent Tomography (OCT)...
October 2016: Saudi Journal of Ophthalmology: Official Journal of the Saudi Ophthalmological Society
https://www.readbyqxmd.com/read/27999699/location-of-a-dexamethasone-implant-at-the-macula-after-intravitreal-injection-in-a-silicone-oil-filled-eye
#12
Cenap Mahmut Esenulku, Murat Gunay
Here, we report a case with cystoid macular edema (CME) due to central retinal vein occlusion (CRVO) presented with a dexamethasone implant (Ozurdex) trapped at the macula in her silicone oil- (SO-) filled eye after injection. No additional complications such as intraocular pressure (IOP) rise or retinal damage were observed. The CME was resolved during the follow-up period. At the last visit, 3 months following the injection, Ozurdex implant was found to be mostly dissolved without any additional ocular complications...
2016: Case Reports in Ophthalmological Medicine
https://www.readbyqxmd.com/read/27911446/treatment-patterns-of-ranibizumab-intravitreal-injection-and-dexamethasone-intravitreal-implant-for-retinal-vein-occlusion-in-the-usa
#13
S Nghiem-Buffet, S Baillif, S Regnier, A Skelly, N Yu, A Sodi
PurposeRanibizumab, an anti-vascular endothelial growth factor, and dexamethasone, a corticosteroid, have been shown to be effective in treating macular oedema secondary to retinal vein occlusion (RVO) (central RVO (CRVO) and branch RVO (BRVO)). Their real-world usage, however, has yet to be compared. We therefore evaluated ophthalmology visits for both drugs using US patient-level data.MethodsThe IMS Health Real-World Data Medical Claims database was used to identify treatment-naive patients receiving ranibizumab intravitreal injections or dexamethasone intravitreal implants between June 2010 and February 2014 who had 12 months of follow-up data...
December 2, 2016: Eye
https://www.readbyqxmd.com/read/27911421/-analysis-of-changes-in-central-macular-thickness-based-on-optical-coherence-tomography-angiography-findings-in-retinal-vein-occlusion
#14
M V Budzinskaya, A V Shelankova, M A Mikhailova, A A Plyukhova, N M Nurieva, A V Fomin
AIM: To investigate the relationship between OCT angiography measurements and central fundus changes in patients with retinal vein occlusion (RVO). MATERIAL AND METHODS: The study enrolled 21 RVO patients aged from 55 to 86 years (69.9±2.28 years), including 8 patients with ischemic central RVO (I-CRVO; 73.6±3.4 years on average) and 13 patients with branch RVO (BRVO; 67.6±3.0 years on average). Of the latter, 8 cases were ischemic (I-BRVO) and 5 non-ischemic (NI-BRVO)...
2016: Vestnik Oftalmologii
https://www.readbyqxmd.com/read/27903073/comparison-between-early-or-late-intravitreal-injection-of-dexamethasone-implant-in-branch-brvo-or-central-crvo-retinal-vein-occlusion-six-months-follow-up
#15
Fernanda Pacella, Giuseppe La Torre, Stefania Basili, Monica Autolitano, Antonella Pascarella, Tommaso Lenzi, Elena Pacella
PURPOSE: The purpose of this study was to compare early and late injections of intravitreal dexamethasone implant in patients affected by central retinal vein occlusion (CRVO) or branch retinal vein occlusion (BRVO) with a six-month follow-up. We assessed whether an earlier treatment start (within 7 days from diagnosis) could be more beneficial than a delayed (or late) treatment start (after 7 days). MATERIALS AND METHODS: The study included 81 patients (81 eyes) affected by retinal vein occlusion...
November 30, 2016: Cutaneous and Ocular Toxicology
https://www.readbyqxmd.com/read/27902540/macular-perivenous-retinal-whitening-and-presumed-retino-ciliary-sparing-in-a-recurrent-central-retinal-vein-occlusion-associated-with-the-antiphospholipid-syndrome-and-cryoglobulinemia
#16
Dov B Sebrow, Jesse J Jung, Jason Horowitz, Jeffrey G Odel, K Bailey Freund
PURPOSE: Macular perivenous retinal whitening results from hypoperfusion-induced ischemia of the middle retina that can occur in central retinal vein occlusion (CRVO). We describe an unusual case of recurrent CRVO with macular perivenous retinal whitening and retino-ciliary venous sparing in the setting of 2 prothrombotic diseases, antiphospholipid syndrome and Type II cryoglobulinemia. METHODS: A 50-year-old man presented with intermittent loss of vision in his right eye related to a recurrent CRVO...
November 29, 2016: Retinal Cases & Brief Reports
https://www.readbyqxmd.com/read/27893623/efficacy-and-safety-of-intravitreal-conbercept-injections-in-macular-edema-secondary-to-retinal-vein-occlusion
#17
Zuhua Sun, Haiying Zhou, Bing Lin, Xuan Jiao, Yingdong Luo, Feng Zhang, Shanshan Tao, Quan Wu, Zunhong Ke, Xiaoling Liu
PURPOSE: To assess the efficacy and safety of intravitreal conbercept injections in patients with macular edema secondary to retinal vein occlusion (RVO). METHODS: A prospective, Phase II clinical trial was performed on 60 patients with macular edema secondary to RVO. Thirty patients had branch RVO (BRVO) and 30 had central RVO (CRVO). Each patient received intravitreal injections of conbercept monthly up to 3 months, followed by monthly evaluation and injection pro re nata to Month 9...
November 23, 2016: Retina
https://www.readbyqxmd.com/read/27863843/score2-report-2-study-design-and-baseline-characteristics
#18
Ingrid U Scott, Paul C VanVeldhuisen, Michael S Ip, Barbara A Blodi, Neal L Oden, Maria Figueroa, Pravin U Dugel
PURPOSE: To describe the design and baseline characteristics of participants in the Study of COmparative Treatments for REtinal Vein Occlusion 2 (SCORE2) and to compare with cohorts from other retinal vein occlusion trials. DESIGN: Phase III prospective, multicenter, randomized clinical trial designed to assess whether intravitreal bevacizumab is noninferior to intravitreal aflibercept for treatment of decreased vision attributable to macular edema associated with central retinal vein occlusion (CRVO) or hemiretinal vein occlusion (HRVO)...
February 2017: Ophthalmology
https://www.readbyqxmd.com/read/27847619/central-retinal-vein-occlusion-concomitant-with-dengue-fever
#19
Punithamalar Velaitham, Nandini Vijayasingham
BACKGROUND: Dengue virus infection is on the rise and there is increasing number of ocular complications that are being reported. Most common ocular complications are macular edema, macular hemorrhages, and foveolitis. There are case reports on branch retinal vessel occlusions. Most of the ocular complications are attributed to the bleeding tendency and transudative process in dengue viral infection. This is a case report of ischemic central retinal vein occlusion (CRVO) concomitant with dengue fever...
2016: International Journal of Retina and Vitreous
https://www.readbyqxmd.com/read/27769324/effect-of-aflibercept-on-refractory-macular-edema-associated-with-central-retinal-vein-occlusion
#20
Michael N Cohen, Samuel K Houston, Alexander Juhn, Allen C Ho, Carl D Regillo, James Vander, Allen Chiang
OBJECTIVE: To report short-term visual and anatomic outcomes of patients who were switched to aflibercept for persistent macular edema associated with central retinal vein occlusion (CRVO). METHODS: Retrospective, consecutive, interventional case series of 17 patients with persistent macular edema secondary to CRVO (defined as intraretinal edema and either <50 µm reduction in central foveal thickness [CFT] or worsening or no improvement in visual acuity [VA] compared to baseline) despite anti-VEGF treatment who were switched to aflibercept treatment...
October 2016: Canadian Journal of Ophthalmology. Journal Canadien D'ophtalmologie
keyword
keyword
44183
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"